受体导向药物L-HAS-Ara-AMP抗HBV效应的临床研究

CLINICAL STUDY ON THE ANTI-HBV EFFECT OF L-HAS-Ara-AMP-A RECEPTOR TARGETED DRUG

目的：观察去唾液酸糖蛋白受体导向药物L－HAS－Ara－AMP的抗HBV临床疗效。方法：应用5d和28d疗程治疗慢性乙型肝炎29例，以Ara－AMP治疗27例为对照。结果：L－HSA－Ara－AMP5d疗程，10例HBeAg阳性阴转3例，8例HBV－DNA阳性阴转4例。28d疗程HBeAg阴转31.6％，HBeAg滴度下降率47．4％，有治疗效应者790％；HBV－DNA阴转率31．6％。5d疗程治疗结束1月时部分HBeAg和HBV－DNA已复阳。28d疗程治疗结束3月时阴转的病例仍为阴性。L－HSA－Ara－AMP组未发现任何不良反应。结论：L－HSA－Ara－AMP组的Ara-AMP实际用量大大减少仍具有与单用Ara－AMP相似或略优的抗病毒效果，并且毒副作用减少。

To observe the clinical efficacy of L-HAS-Ara-AMP (lactoaminated human serum albumin arabinoside adenine monophosphate), a receptor targeted drug. METHODS: 56 patients with chronic hepatitis B were entered into the study. 29 of them were treated with L-HASAra-AMP in a daily dose of 35 mg/kg for 5 days or 28 days;the rest were used as control and treated with Ara-AMP in a daily dose of 10 mg/kg. RESULTS: In the 5 days group, there are 10 patients with positive HBeAg and 8 patients with positive HBV-DNA, after treatment 3 of the former and 4 of the later temporaryly turned into negative and reversed a month later. In the 28 days group, a HBeAg negative-turning rate of 31. 65%, a HBeAg titer decresing rate of 47. 4 %, and an effective rate of 79. 0 %were obtained after treatment, these parameters didn' t reversed even 3 months later. No adverse rections were observed. CONCLUSION: L-HAS-Ara-AMP is effective in treatment of HBV infections and its anti-viral activity even in very low doses is more powerful than that of free Ara-AMP with no obvious side effects.